Precigen (PGEN) | Financial Analysis & Statements
Precigen Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
4.6M
Gross Profit
3.0M
65.04%
Operating Income
-21.7M
-474.61%
Net Income
-23.5M
-514.85%
Balance Sheet Metrics
Total Assets
155.5M
Total Liabilities
134.6M
Shareholders Equity
20.9M
Debt to Equity
6.44
Cash Flow Metrics
Operating Cash Flow
-23.9M
Free Cash Flow
-23.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Precigen Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 9.7M | 3.9M | 6.2M | 26.9M | 14.3M |
| Cost of Goods Sold | 4.8M | 4.3M | 6.1M | 6.3M | 5.7M |
| Gross Profit | 4.9M | -342.0K | 106.0K | 20.6M | 8.5M |
| Gross Margin % | 50.2% | -8.7% | 1.7% | 76.4% | 59.7% |
| Operating Expenses | |||||
| Research & Development | 41.3M | 53.1M | 48.6M | 47.2M | 47.9M |
| Selling, General & Administrative | 70.1M | 41.3M | 40.4M | 48.0M | 52.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 111.5M | 94.4M | 89.0M | 95.2M | 99.9M |
| Operating Income | -106.6M | -94.7M | -88.9M | -74.6M | -91.4M |
| Operating Margin % | -1,100.8% | -2,412.9% | -1,428.5% | -277.3% | -640.7% |
| Non-Operating Items | |||||
| Interest Income | 3.2M | 1.4M | 3.2M | 133.0K | 171.0K |
| Interest Expense | 3.9M | 6.0K | 468.0K | 6.8M | 18.8M |
| Other Non-Operating Income | -143.4M | -34.7M | -10.2M | 1.3M | -978.0K |
| Pre-tax Income | -250.6M | -128.0M | -96.4M | -80.0M | -111.0M |
| Income Tax | 3.0K | -1.8M | -458.0K | -189.0K | -160.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -250.6M | -126.2M | -95.9M | 28.3M | -92.2M |
| Net Margin % | -2,588.2% | -3,216.2% | -1,540.6% | 105.2% | -646.0% |
| Key Metrics | |||||
| EBITDA | -100.1M | -83.2M | -78.4M | -61.3M | -77.9M |
| EPS (Basic) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 |
| EPS (Diluted) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 |
| Basic Shares Outstanding | 312980562 | 267727426 | 244536221 | 200360821 | 197759900 |
| Diluted Shares Outstanding | 312980562 | 267727426 | 244536221 | 200360821 | 197759900 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Precigen Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 30.2M | 29.5M | 7.6M | 4.9M | 36.4M |
| Short-term Investments | 67.6M | 68.4M | 55.3M | 51.1M | 72.2M |
| Accounts Receivable | 3.9M | 926.0K | 902.0K | 978.0K | 1.3M |
| Inventory | 9.6M | - | - | 287.0K | 326.0K |
| Other Current Assets | 3.4M | 3.3M | 4.3M | 5.1M | 5.5M |
| Total Current Assets | 115.2M | 102.4M | 68.8M | 118.2M | 156.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 24.1M | 21.8M | 25.7M | 26.1M | 26.8M |
| Goodwill | 33.6M | 42.7M | 93.9M | 118.3M | 127.4M |
| Intangible Assets | 3.2M | 4.5M | 40.7M | 44.5M | 52.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 982.0K | 459.0K | 846.0K | 1.1M | 46.3M |
| Total Non-Current Assets | 40.3M | 42.9M | 82.3M | 97.8M | 203.2M |
| Total Assets | 155.5M | 145.3M | 151.0M | 216.0M | 359.9M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 12.0M | 3.5M | 1.7M | 4.1M | 3.1M |
| Short-term Debt | 1.1M | 956.0K | 1.2M | 44.4M | 1.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 12.9M |
| Total Current Liabilities | 37.3M | 21.5M | 23.0M | 78.6M | 34.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 97.2M | 4.5M | 5.9M | 7.0M | 188.6M |
| Deferred Tax Liabilities | - | 0 | 1.8M | 2.3M | 2.5M |
| Other Non-Current Liabilities | 134.0K | - | - | - | 50.0K |
| Total Non-Current Liabilities | 97.3M | 85.2M | 9.6M | 11.1M | 217.9M |
| Total Liabilities | 134.6M | 106.8M | 32.5M | 89.7M | 252.5M |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -2.3B | -2.1B | -2.0B | -1.9B | -1.9B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 20.9M | 38.5M | 118.5M | 126.3M | 107.3M |
| Key Metrics | |||||
| Total Debt | 98.3M | 5.5M | 7.1M | 51.4M | 190.1M |
| Working Capital | 77.9M | 80.9M | 45.8M | 39.5M | 122.0M |
Balance Sheet Composition
Precigen Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -250.6M | -126.2M | -95.9M | 28.3M | -92.2M |
| Depreciation & Amortization | 3.2M | 4.5M | 6.7M | 10.8M | 13.8M |
| Stock-Based Compensation | 10.9M | 9.5M | 9.9M | 10.2M | 13.9M |
| Working Capital Changes | 585.0K | 5.4M | 15.5M | -34.5M | -3.2M |
| Operating Cash Flow | -235.8M | -109.7M | -77.4M | -65.3M | -61.3M |
| Investing Activities | |||||
| Capital Expenditures | -2.0M | -8.6M | -1.5M | -4.9M | -7.2M |
| Acquisitions | - | - | - | - | 0 |
| Investment Purchases | -208.0M | -187.2M | -185.0M | 0 | -174.2M |
| Investment Sales | 208.5M | 175.0M | 183.4M | 68.4M | 100.2M |
| Investing Cash Flow | -1.5M | -20.7M | -3.1M | 64.1M | -74.5M |
| Financing Activities | |||||
| Share Repurchases | -2.2M | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 92.8M | - | - | - | 0 |
| Debt Repayment | 0 | 0 | -43.2M | -155.3M | -466.0K |
| Financing Cash Flow | 88.8M | 110.2M | 29.6M | -155.9M | 120.6M |
| Free Cash Flow | -89.8M | -76.8M | -68.5M | -70.0M | -63.0M |
| Net Change in Cash | -148.5M | -20.2M | -50.9M | -157.1M | -15.3M |
Cash Flow Trend
Precigen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-2.89
Forward P/E
-18.00
Price to Book
67.12
Price to Sales
144.73
PEG Ratio
-18.00
Profitability Ratios
Profit Margin
50.20%
Operating Margin
-474.61%
Return on Equity
-571.97%
Return on Assets
-44.30%
Financial Health
Current Ratio
3.09
Debt to Equity
470.04
Beta
1.12
Per Share Data
EPS (TTM)
$-1.37
Book Value per Share
$0.06
Revenue per Share
$0.03
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PGEN | 1.4B | -2.89 | 67.12 | -571.97% | 50.20% | 470.04 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






